Nektar Therapeutics | NKTR - Cash And Equivalent


Nektar Therapeutics reported $149.58M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 13.99B 1.95B Jun/2026
Baxter International USD 2.15B 133M Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Cara Therapeutics USD 19.85M 883K Mar/2026
Cipla INR 10.18B 2.22B Mar/2026
Dr.Reddys Laboratories INR 11.2B 4.16B Jun/2026
Eisai JPY 245.42B 56.22B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Exelixis USD 281.45M 55.3M Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Incyte USD 3.98B 33.45M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
MacroGenics USD 113.91M 47.39M Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Pfizer USD 976M 727M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Takeda JPY 460.98B 134.07B Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
Xencor USD 44.66M 30.49M Jun/2026